Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
The present study was designed to investigate the modulatory effect of the anti-estrogen, tamoxifen (Tam) on epirubicin (Epi) cytotoxicity in breast cancer cell lines; MCF-7 and NCI-adr. Using sulphorhodamine-B assay, NCI-adr cell line was found to be five-folds more resistant to the cytotoxic effect of Epi as compared to MCF-7 cell line. Pretreatment of cells with Tam was observed to enhance Epi cytotoxicity by 4.3- and 6.5-folds in MCF-7 and NCI-adr cells, respectively. Tam-Epi interaction was found to be additive in MCF-7 cells and synergistic in NCI-adr cells. Flowcytometric DNA ploidy analysis revealed that, Epi induced cell arrest at G2/M phase. Tam pretreatment enhanced the blocking activity of low dose of Epi in MCF-7 and induced nearly two-fold increase in the percentage of S phase in NCI-adr cells. Determination of cellular Epi level revealed that Tam induced a significant increase in intracellular Epi accumulation only in NCI-adr cells after 48 h. However, analysis of P-gp function revealed that Tam failed to modulate P-gp function in both cell lines. Also, assessment of topoisomerae IIalpha gene expression showed that neither Epi nor Tam managed to change its expression level. In conclusion, Tam potentiates Epi cytotoxicity in sensitive and resistant breast cancer cell lines. This potentiation can be explained by an enhancement of cell accumulation in S and G2/M phase, at which the cells are most sensitive to the cytotoxic effect of Epi as well as an increase in the intracellular level of Epi in resistant cell line.
Azab
Samar S
SS
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Egypt.
El-Demerdash
Ebtehal
E
Abdel-Naim
Ashraf B
AB
Youssef
Ekram
E
El-Sharkawy
Nahla
N
Osman
Abdel-Moneim M
AM
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004250:DNA Topoisomerases, Type II / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D013629:Tamoxifen; D015251:Epirubicin; D004250:DNA Topoisomerases, Type II